Zydus Lifesciences Ltd - 532321 - Update
Update-USFDA Inspection02-06-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Post Results Earnings Call held on May 18, 202324-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of extracts of audited financial results for the quarter / year ended on March 31, 2023 in Financial Express on May 19, 2023.19-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the provisions of regulations 30 and 46(2)(oa) of the Listing Regulations, we hereby inform that the audio recording of the Company's Investor Call discussing about the financial results for the quarter / year ended March 31, 2023 is available on the Company's website.18-05-2023
Zydus Lifesciences Ltd - 532321 - Related Party Transactions
Pursuant to the provisions of regulation 23(9) of the Listing Regulations, please find enclosed the details of Related Party Transactions for the half year ended on March 31, 2023, in the prescribed format.18-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals firm Zydus Lifesciences announced Q4FY23 & FY23 results: Q4FY23: Revenue from Operations at Rs 50,106 million, up 32% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 3,541 million (7.1% of revenues). EBITDA for the quarter was Rs 12,556 million, up 75% YoY. EBITDA margin for the quarter was 25.1% against 18.9% in Q4 FY22. Adjusted for one-time COVID related inventory provision of Rs 1,435 million made in Q4 FY22, EBITDA grew by 46% YoY. Net Profit adjusted for the exceptional expense in Q4 FY23 was Rs 8,979 million, up 126% YoY. Excluding the exceptional expense, one-time COVID related inventory provision and profit/ (loss) of discontinued operations, net profit was up by 71% YoY. Capex (organic) for the quarter was Rs 2,040 million. FY23: Revenue from Operations at Rs 1,72,374 million, up 14% over last year. Research & Development (R&D;) investments for the year stood at Rs 12,363 million (7.2% of revenues). Reported EBITDA for the year was Rs 38,599 million, up 16% YoY. EBITDA margin for the year was 22.4% against 22.1% last year. Adjusted for COVID related inventory provision made in FY23 and FY22, EBITDA margin for the year was 23.1% against 23.3% last year. Net Profit adjusted for the exceptional items and profit/ (loss) of discontinued operations, was Rs 25,691 million, up 19% YoY. Capex (organic) for the year was Rs 9,579 million. Net Debt to Equity ratio as on 31st March, 2023 was -0.03x while Net Debt to EBITDA stood at -0.14x at the end of March, 2023. Net Cash (negative Net Debt) as on March 31, 2023 was Rs 5,461 million. We are delighted to have maintained growth momentum across all our key businesses throughout the year, ending the fiscal year on a strong note with steady improvement in profitability and balance sheet health. We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth, the US business continuing to leverage our robust product pipeline and agile supply chain and scale-up of our emerging market business. We are committed to upholding high quality management standards and working constantly to enhance them. We are advancing our innovation efforts with an aim to serve the patients’ needs across markets and improving their health outcomes. Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited Result PDF18-05-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Compliance under regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201518-05-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Independent Director of the Company18-05-2023
Zydus Lifesciences Ltd - 532321 - Record Date For Final Dividend - July 28, 2023
Record Date For Final Dividend - July 28, 202318-05-2023